A Retrospective Study of Clinical and Economic Burden of Focal Segmental Glomerulosclerosis (FSGS) in the United States.

Kalantar-Zadeh, Kamyar; Baker, Christine L; Copley, J Brian; Levy, Daniel I; Berasi, Stephen; Tamimi, Nihad; Alvir, Jose; Udani, Suneel M

Kalantar-Zadeh, Kamyar; Baker, Christine L; Copley, J Brian; Levy, Daniel I; Berasi, Stephen; Tamimi, Nihad; Alvir, Jose; Udani, Suneel M.

Afiliación

Kalantar-Zadeh K; University of California Irvine, School of Medicine, Irvine, CA, USA.
Baker CL; Pfizer Inc., New York, NY, USA.
Copley JB; Pfizer Inc., New York, NY, USA.
Levy DI; Pfizer Inc., New York, NY, USA.
Berasi S; Pfizer Inc., New York, NY, USA.
Tamimi N; Medicopharma Solutions Ltd. Canterbury, Kent, UK.
Alvir J; Pfizer Inc., New York, NY, USA.
Udani SM; Chicago Glomerular Disease Institute, Chicago, IL, USA.

Kidney Int Rep ; 6(10): 2679-2688, 2021 Oct.

Article en En | MEDLINE | ID: mdl-34622107

Palabras clave

claims analysis; costs; economic burden; focal segmental glomerulosclerosis; health care resource utilization; nephrotic range proteinuria

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Tipo de estudio: Health_economic_evaluation / Observational_studies / Risk_factors_studies Idioma: En Revista: Kidney Int Rep Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google